X4 Pharmaceuticals, Inc.: updates and filings

XFORNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$2.96

November 19, 2026Market cap $302M

What Ploutos Investor adds for X4 Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 78 daysAround Feb 5, 2027 · for Q4 2026

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 17, 2026 latest annualNov 4, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 29, 2026Other material events
    Form8-K
  • Oct 8, 2026Material agreement entered, material agreement ended, new material financial obligation, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Oct 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 21, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 9, 2026Other material events
    Form8-K
  • Sep 8, 2026Other material events
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jul 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 1, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Filing
    FormEFFECT
  • May 13, 2026Officer or director change, shareholder vote (amendment)
    Form8-K/A
  • May 12, 2026Officer or director change, shareholder vote
    Form8-K
  • May 12, 2026Correspondence with the SEC
    FormCORRESP
  • May 11, 2026Letter from the SEC
    FormUPLOAD
  • May 6, 2026Shelf registration for future offerings
    FormS-3
  • May 6, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Mar 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Mar 20, 2026Additional annual meeting material
    FormDEFA14A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 24, 2010.

The full analysis

What do X4 Pharmaceuticals's filings show?

The filings are where every one of X4 Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.